Clinical trials: Proton Therapy
- Condition Proton Therapy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Gastroesophageal Reflux Disease (GERD)
The EndoGastric Solutions TEMPO Trial
The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal…
- Trial name
- TEMPO (NCT01647958)
- Testing
- EsophyX System with SerosaFuse fasteners, PPI
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- EndoGastric Solutions
Pharmacokinetics
Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T
This study evaluate the pharmacokinetic and safety of IY-NT-T in healthy adults
- Trial name
- NCT05509543
- Testing
- IY-NT-T, IY-NT-R
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T
This study evaluate the pharmacokinetic and safety of IY-NT-T in healthy adults
- Trial name
- NCT05617651
- Testing
- IY-NT-T, IY-NT-R
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Bioavailability, B-cell Lymphoid Cancer
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
This study will be a 2-part, open-label, single-center relative bioavailability, PPI effect, food-effect and particle size effect randomized crossover study of acalabrutinib tablets in healthy subjects (males or females).
- Trial name
- NCT04488016
- Testing
- Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.
This is an open-label, randomized, cross-over, single dose study in healthy volunteers to evaluate the potential effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of crizotinib.
- Trial name
- NCT01549574
- Testing
- crizotinib, esomeprazole
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants.
- Trial name
- NCT05338502
- Testing
- Selpercatinib, Ranitidine, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
This is a Phase I, randomized, two-part, single-center pharmacokinetics (PK) study to assess the relative bioavailability of capsule and tablet formulations of GDC-0941 in the fasted state (Part 1) and to determine the effect of…
- Trial name
- NCT00999128
- Testing
- GDC-0941, rabeprazole
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.
- Trial name
- NCT05826574
- Testing
- Brensocatib, Rifampin, Esomeprazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Healthy Subjects
Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
This study will be conducted to evaluate the effect of lemborexant 10 milligrams (mg) (at steady state) on the pharmacokinetics (PK) of a single-dose combined oral contraceptive, Loestrin 1.5/30 (containing 0.030 mg of ethinyl…
- Trial name
- NCT03451110
- Testing
- lemborexant, Loestrin, famotidine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy Participants
A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants
This is a Phase 1, open-label, randomized, two-part study to evaluate the relative bioavailability (rBA) of two tablet formulations compared to the capsule formulation of ZN-A-1041 (Part 1).
- Trial name
- NCT07051993
- Testing
- ZN-A-1041
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body.
- Trial name
- NCT00746733
- Testing
- Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteers
A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK.
- Trial name
- NCT06793943
- Testing
- Zasocitinib, COC, Metformin
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Participants
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants.
- Trial name
- NCT07643272
- Testing
- HMPL-760, Rabeprazole and HMPL-760
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Healthy
Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)
This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy…
- Trial name
- NCT07888569
- Testing
- DZD8586, Rabeprazole
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Healthy
Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
To investigate the effect of acid reducing agents (an antacid and an H2-receptor antagonist and a proton pump inhibitor) on palbociclib bioavailability in the presence of food.
- Trial name
- NCT02097329
- Testing
- palbociclib commercial free base, famotidine, rabeprazole
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Amyotrophic Lateral Sclerosis
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
This study will evaluate the pharmacokinetics and safety of GDC-0134 in healthy female volunteers of non-childbearing potential.
- Trial name
- NCT03237741
- Testing
- Reference capsule GDC-0134, Prototype capsule GDC-0134, rabeprazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Hypergastrinaemia
Effects of YF476 and Rabeprazole on Gastric Function
The primary objectives are to find out in healthy subjects if: YF476 prevents the ECL-cell hyperplasia induced by repeated doses of rabeprazole - a proton pump inhibitor; YF476 also prevents rebound hyperacidity after stopping…
- Trial name
- NCT01699113
- Testing
- YF476, Rabeprazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole
This is a two-part study to be conducted at single study center, (additional center(s) may be selected if needed) to assess the safety, tolerability, PK and PD parameters for a new SDD formulation of CC-11050 in healthy subjects.
- Trial name
- NCT04139226
- Testing
- CC-11050
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults.
- Trial name
- NCT02638116
- Testing
- Ibrutinib, Omeprazole
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)
Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole.
- Trial name
- NCT01918176
- Testing
- Palbociclib alone, Palbociclib + Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer